Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market is set to reach US$ 929.05 million by 2033, at a strong CAGR of 18.1%. North America leads the market with 42.1% market share.

The Metabolic Dysfunction-Associated Steatohepatitis (MASH) market size reached US$ 180.1 million in 2024 is expected to reach US$ 929.05 million by 2033, growing at a CAGR of 18.1% during the forecast period 2025-2033. The global obesity rate rising continuously with approximately 2.3 billion children and adults are living with overweight or obese, creating a direct risk for MASH. Type 2 diabetes is another significant risk factor, with an estimated 462 million individuals many of whom are at high risk of developing MASH.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a progressive liver disease linked to metabolic disorders, characterized by fat accumulation, inflammation, and liver cell damage, increasing risk of fibrosis, cirrhosis, and liver-related complications.

DataM Intelligence unveils its latest report on the " Metabolic Dysfunction-Associated Steatohepatitis Market size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-mash-market?prtk

United States: Key Industry Developments (2025)

✅ December 2025: The U.S. FDA qualified PathAI's AIM‐MASH AI pathology biomarker tool under its Drug Development Tool program, marking the first AI‐assisted biomarker qualified for MASH clinical development and aiding faster drug evaluation/stratification.

✅ October 2025: Gilead Sciences advanced clinical trials for novel antifibrotic therapeutic candidates targeting MASH, accelerating pipeline options aimed at reducing liver fibrosis and inflammation.

✅ September 2025: Novo Nordisk initiated combination studies of GLP‐1 analogues with other agents to enhance therapeutic benefit for MASH and systemic metabolic dysfunction, signaling innovation beyond mono‐therapy.

✅ August 2025: FDA granted Fast‐Track designations to several emerging drug candidates focused on MASH to expedite development/approval pathways in severe liver fibrosis and metabolic dysfunction.

✅ August 2025: Novo Nordisk's Wegovy (semaglutide 2.4 mg) received accelerated FDA approval for treatment of noncirrhotic MASH with moderate to advanced liver fibrosis, becoming the first GLP‐1 therapy available for this indication in the U.S. market.

Japan: Key Industry Developments (2025)

✅ October 2025: Takeda Pharmaceutical entered a strategic collaboration to develop a novel PPAR agonist therapy for MASH patients in Asian populations, marking significant regional R&D expansion.

✅ October 2025: The Pharmaceuticals and Medical Devices Agency (PMDA) established expedited review pathways for MASH therapies, aiming to accelerate regulatory assessment of novel metabolic and fibrosis‐targeted agents.

✅ October 2025: Mitsubishi Tanabe Pharma initiated a large‐scale biomarker discovery program to support precision treatment strategies and early disease progression monitoring in MASH clinical cohorts.

✅ February 2025: Inventiva and Hepalys Pharma began clinical development of lanifibranor in Japan, dosing the first participants in a Phase 1 program targeting metabolic dysfunction‐associated steatohepatitis to address unmet treatment needs.

📌 Metabolic Dysfunction-Associated Steatohepatitis Market 2025-26 M&A Deals

→ In January 2026, Novo Nordisk acquired a clinical‐stage biotech specializing in next‐generation GLP‐1 and FGF21 dual agonists to accelerate its MASH drug pipeline. The acquisition was aimed at expanding beyond semaglutide‐based therapies into advanced metabolic and liver disease assets. Deal terms (exact amount) were disclosed as part of strategic asset expansion, though precise financial details were not fully publicized.

→ In December 2025, Madrigal Pharmaceuticals secured a strategic licensing and co‐development agreement with a global pharma partner for resmetirom (Rezdiffra) combinations in advanced MASH fibrosis. This deal includes collaboration terms and commercialization rights; specific upfront and milestone figures were disclosed in company releases tied to a strategic alliance.

→ In November 2025, Inventiva entered into a collaboration and equity investment agreement with a major pharmaceutical company to advance lanifibranor Phase III trials and expand its MASH therapeutic footprint. Financial terms include both equity investment and potential milestone‐linked payments supporting late‐stage development.

→ In October 2025, Novo Nordisk agreed to acquire Akero Therapeutics (a U.S. biotech focused on MASH) for up to $5.2 billion, including approximately $4.7 billion upfront and a contingent value right (CVR) worth up to $500 million tied to regulatory and commercial milestones. This deal brings efruxifermin, a late‐stage FGF21 analog, into Novo's portfolio to strengthen its metabolic/liver disease pipeline.

→ In September 2025, Roche announced the acquisition of 89bio for up to $3.5 billion, comprising an upfront cash component of about $2.4 billion plus potential contingent value rights of up to $1.1 billion. The acquisition adds pegozafermin, an FGF21 analog in Phase III development for MASH, to Roche's metabolic disease franchise.

→ In July 2025, GlaxoSmithKline (GSK) completed its acquisition of Boston Pharmaceuticals' efimosfermin alfa program for approximately $2.0 billion (about $1.2 billion upfront plus up to $800 million in milestone payments). This FGF21 analog is being developed for metabolic dysfunction‐associated steatohepatitis (MASH) and related steatotic liver diseases.

Metabolic Dysfunction-Associated Steatohepatitis Market Drivers:-
⏩ Worldwide obesity and overweight figures have ballooned into the billions, with trends pointing toward continued growth.

⏩ As a result, the prevalence of MASH is expanding rapidly, which directly fuels diagnosis rates and demand for therapeutic intervention.

⏩ Rising incidence translates into a broader addressable patient base, which underpins forecasted market expansions with strong CAGR figures in the teens and 20s through 2030s.

⏩ Resmetirom (Rezdiffra) approval in 2024 marked a turning point; it's the first therapy with demonstrated histological improvement and fibrosis reduction.

⏩ This approval shifted the market from "unmet need" to "tangible commercial runway", attracting investment and enabling pricing and reimbursement discussions globally.

⏩ GLP‐1 receptor agonists, FGF21 analogs, PPAR agonists, THR‐β agonists, ACC inhibitors, and dual agonist mechanisms.

⏩ Over 80 % of late‐stage candidates target metabolic and fibrotic pathways, positioning the market for continued growth beyond current drugs.

⏩ Strategic M&A activity (e.g., acquisitions, partnerships) underscores investor confidence and commercial prioritization of MASH assets.

⏩ Development of non‐invasive diagnostics (biomarkers, blood panels, imaging) expands early diagnosis - a key factor because MASH is asymptomatic in early stages.

⏩ Earlier detection increases treatment uptake and expands patient adherence, which feeds back into market revenue forecasts.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=metabolic-dysfunction-associated-steatohepatitis-mash-market?prtk

Metabolic Dysfunction-Associated Steatohepatitis Major Players:-

Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Inventiva, and Hepalys Pharma, all investing heavily in next-generation MASH therapies targeting metabolic, inflammatory, and fibrotic pathways.

Key players highlights:-

1. Madrigal Pharmaceuticals
Madrigal leads the MASH treatment market with its first‐approved MASH drug, Rezdiffra (resmetirom) targeting metabolic, inflammatory and fibrotic pathways.
It held approximately 7% global market share in 2024, leading early commercial adoption.

2. Novo Nordisk
Novo Nordisk is expanding in MASH with its GLP‐1 therapy Wegovy (semaglutide) newly approved for MASH fibrosis, leveraging its metabolic disease expertise.
Market share is estimated at around 1% in 2024, with growth expected as its MASH pipeline and acquisitions scale.

3. Boehringer Ingelheim
Boehringer Ingelheim is advancing dual GLP‐1/glucagon agonists like survodutide to address both metabolic dysfunction and liver pathology in MASH.
It is a key late‐stage innovator, though specific broad market share figures are not publicly quantified yet due to pipeline focus.

4. Inventiva
Inventiva is developing lanifibranor, a pan‐PPAR agonist showing promising Phase II/III MASH resolution and fibrosis improvements.
As an emerging contender, precise current market share isn't widely reported, but it's highlighted as a high‐growth competitor.

5. Hepalys Pharma
Hepalys Pharma is advancing novel agents targeting inflammatory and fibrotic pathways with partnerships to accelerate MASH clinical development.
While market share estimates aren't yet available, its strategic collaborations position it as a notable niche innovator.

Metabolic Dysfunction-Associated Steatohepatitis Regional Highlights
North America
• Holds the largest share of the global MASH market (42.1% share in 2024).
• Growth driven by high prevalence of metabolic disorders and strong pharmaceutical R&D activity.
• Leading clinical trials and regulatory approvals (e.g., resmetirom) support robust market expansion.

Europe
• Represents the second‐largest regional share (28% of global market in 2024).
• Well‐developed healthcare systems and collaborative care models support steady growth.
• Rising clinical activity and regulatory pathways (e.g., conditional authorisations) enhance treatment access.

Asia‐Pacific
• Accounts for 20% share of the global market in 2024 with the fastest projected growth.
• Rapid rise in obesity/diabetes incidence and expanding healthcare infrastructure are key drivers.
• Market expansion bolstered by increasing awareness and investments in diagnostics/treatments.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-mash-market?prtk

Metabolic Dysfunction-Associated Steatohepatitis market segmentation :

The MASH drugs market is segmented by disease stage, covering intraoral and extraoral X-rays, imaging software, and other diagnostic tools. By medication type, it includes 2D digital radiography, 3D CBCT, optical/impression scanners, digital sensors, and hybrid systems, reflecting technological advances in treatment. Route of administration segmentation considers clinical applications such as endodontics, implantology, orthodontics, oral and maxillofacial surgery, and other specialties, highlighting targeted drug delivery and patient-specific approaches.

Q: What is driving the growth of the Metabolic Dysfunction-Associated Steatohepatitis Market?
A: Increasing prevalence of metabolic disorders, rising awareness, and advancements in therapeutic options are key growth drivers.

Q: Which regions hold the largest share in the Metabolic Dysfunction-Associated Steatohepatitis Market?
A: North America leads the market, followed by Europe, with Asia-Pacific showing rapid growth potential.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.